Herantis Pharma Oyj (HLSE: HRTIS)
Health Care · Pharmaceuticals · FI
€1.53
-14.22% today · -13.9% 1Y
Herantis Pharma Oyj (HLSE: HRTIS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $47.40M and employs 13 people.
Over the last twelve months the share price has lost 13.9%, trading between 1.44 and 3.87.
Tweenvest scores Herantis Pharma Oyj across four factors: quality 30/100, value 71/100. Its strongest factor is value.
HRTIS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $47.40M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.27
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- €3.87
- 52-week low
- €1.44
- Avg volume (3M)
- —
- Shares outstanding
- 26.50M
- Employees
- 13
- Next earnings
- —
About Herantis Pharma Oyj
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
- ISIN
- FI4000087861
- Founded
- 2008
- Listed since
- Jun 11, 2014
- Exchange
- OMX Nordic Exchange Helsinki
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.